•  
  •  
  •  
  •  

2026-07-22 07:26:07

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore

Keywords Selected:  ZeroObservation

Stock Report

  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations
  • Lupin Bioresearch Center receives Zero Observations from U.S. FDA after Successful Inspection and Assessment
  • USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations
  • Emcure Pharmaceuticals Ltd successfully completes USFDA PAI of Oncology facility
  • Wanbury Limited successfully completes ANVISA audit at its Tanuku plant
  • Alembic Pharmaceuticals Ltd's Oncology facility successfully completes USFDA inspection
  • U.S. FDA inspection at Glenmark Pharmaceuticals Ltd's Facility at Chhatrapati Sambhaji Nagar, India
  • ANVISA - Brazil completes inspection at Caplin Steriles' facility at Gummidipoondi
  • Wanbury's Patalganga Manufacturing Facility clears US FDA Inspection with Zero Observations
  • USFDA completes inspection at Auro Peptides Ltd's facility with zero observations
  • NATCO Pharma announces successful completion of USFDA inspection
  • Granules India successfully completes Two US FDA Audits in a span of 2 weeks
  • USFDA completes inspection at Dr Reddy's Laboratories Ltd's Bollaram API unit
  • USFDA inspection at Zydus' injectables manufacturing facility at Zydus Biotech Park, concludes with Nil observations
  • Alembic Pharmaceuticals Ltd announces Successful completion of USFDA inspection at Derma Facility at Karakhadi
  • US FDA Inspection at JNPC Facility, Visakhapatnam of Gland Pharma Ltd
  • Piramal Pharma Ltd gets zero observations from USFDA for Riverview, Michigan facility
  • SMS Lifesciences India successfully completes USFDA inspection at its API facility
  • USFDA inspection at Torrent's manufacturing facility at Levittown, Pennsylvania, USA

Latest Post

  • CRISIL Limited Reports Q2 CY26 / Q1 FY27 Results: Consolidated Revenue Jumps 27.6% YoY to ₹1,075.39 Crore; Net Profit Reaches ₹216.46 Crore
  • Purple Finance Grants In-Principle Approval to Acquire 100% Stake in Saksham Gram Credit
  • InfoBeans Technologies Reports Q1 FY27 Results: Revenue Jumps 36.6% YoY to ₹152.77 Crore; Net Profit Stands at ₹21.62 Crore
  • Gamco Limited Reports Q1 FY27 Results: Consolidated Revenue Surges 105.8% YoY to ₹113.72 Crore; PAT Reaches ₹32.43 Crore
  • Gabriel India Reports Q1 FY27 Results: Consolidated Revenue Up 15.5% YoY to ₹1,425.68 Crore; Net Profit Reaches ₹108.13 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025